IRONWOOD PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 14.93 million shares for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 14.93M shares.
- IRONWOOD PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 14.93M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month |
|---|---|---|
| 2025-09-30 | 14.93M shares 10-Q · filed 2025-11-10 | 14.93M shares 10-Q · filed 2025-11-10 |
| 2025-06-30 | 14.93M shares 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |